Miclast

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Miclast

Composition and Classification of Miclast

Property Description
Active ingredient Ciclopirox Olamine
Form Cream, Solution, Medicated Nail Polish
Pharmacological class Hydroxypyridone Antifungal Agent
Common use Topical treatment of fungal and yeast infections
Origin Synthetic

Miclast is a branded preparation containing the synthetic active substance Ciclopirox, which is typically formulated as the salt Ciclopirox Olamine. This drug is formally classified as a Hydroxypyridone Antifungal Agent, positioning it within a distinct pharmaceutical category separate from common azole or allylamine medications.

The preparation is identified as a single active ingredient product intended exclusively for topical administration. Its molecular structure, derived from the hydroxypyridone class, provides a documented alternative mechanism of action, functioning by disrupting essential processes within the fungal cell. This confirms that the medication works by chemically interfering with the fungal organism's ability to survive.


Available Forms and Delivery Type

Ciclopirox is available in multiple pharmaceutical preparations to ensure effective treatment across different infected areas, including a cream, a cutaneous solution, and a specialized medicated nail polish (Nail Lacquer). The form determines the composition of the product's base: for instance, the nail lacquer utilizes solvents such as isopropyl alcohol and ethyl acetate to aid penetration into the dense nail structure.

The availability of different forms is strategic, as topical applications require the active substance to be delivered precisely to the site of infection. The formulation of the medicated nail polish is specifically engineered to address the challenges of treating nail fungus and is designed to deliver the agent through the nail plate.


General Benefit and Therapeutic Profile

The overall purpose of Miclast is to eliminate the organisms responsible for dermal infections through both fungicidal (killing the fungus) and fungistatic (stopping its growth) actions. This ensures the medicine addresses the root cause of the infection by preventing the spread and proliferation of the pathogens. A typical neutral use scenario for the cream formulation is the treatment of skin redness and scaling in body folds.

Ciclopirox possesses a broad-spectrum antifungal profile, making it effective against a wide range of yeasts, molds, and dermatophytes. A further benefit of the drug's therapeutic profile is its documented mild anti-inflammatory properties, which contribute to alleviating localized discomfort, such as redness and irritation, often associated with these types of infections.

Regulatory References

  1. Ciclopirox Olamine Cream Label (DailyMed)

What side effects are possible with Miclast?

Possible Side Effects and Safety Information

This section summarizes the official safety profile for Miclast (ciclopirox olamine) as documented in governmental regulatory sources.

Adverse Reactions Scope

Side effects are primarily local and typically mild to moderate in severity. The most frequently reported adverse reactions are those affecting the application site.

Classification Adverse Reaction Examples
Common (Reported in ge 1/100 to <1/10 patients) Application site burning or pain.
Uncommon (Reported in ge 1/1000 to <1/100 patients) Application site pruritus (itching), erythema (redness), rash, discomfort, dryness, and irritation.
Rare or Not Known (Post-marketing reports) Allergic contact dermatitis, bullous dermatitis, hair discoloration, abnormal hair texture, and alopecia (hair loss).

Safety Restrictions and Limitations

Contraindications: The use of this medicine is strictly contraindicated in individuals with a known history of hypersensitivity or allergy to the active substance, ciclopirox olamine, or any of the other components in the formulation.

Population-Specific Safety:

  • Pediatric Use: Safety and effectiveness are generally not established in children under a specific age (e.g., 10 years for some formulations).
  • Pregnancy and Lactation: Use during pregnancy is advised only when the potential benefit is determined to justify the potential risk to the fetus. There is insufficient data on the excretion of the drug in human milk, and caution is advised for use during lactation.

Overdose and Emergency Response

Miclast contains the active ingredient Ciclopirox Olamine, a medicine formulated strictly for topical administration on the skin or nails. Regulatory documents confirm that due to this method of use, the medicine exhibits minimal systemic absorption through the dermal or nail structure. Accordingly, official prescribing information states that no specific systemic overdose symptoms are generally expected to manifest, even in scenarios involving application to unusually large skin areas, high frequency of use, or potential accidental ingestion. This low absorption profile defines the regulatory understanding of overdose presentation.

Despite the low predicted risk for systemic effects, any suspected overdose event requires immediate medical attention as mandated by official regulatory guidance. Instructions from health authorities state that individuals must contact a healthcare practitioner, hospital emergency department, or a regional Poison Control Centre immediately. This urgent action is required even if the affected person is showing no visible signs or symptoms of overdose or discomfort. Seeking immediate professional consultation ensures that appropriate therapeutic intervention can be instituted and the case can be medically monitored. If overdose is suspected, the regulatory guidance is to discontinue use of the product immediately.

Therapeutic Uses of Miclast

What Miclast Treats: Main Uses and Benefits

Miclast is an applied treatment used to manage symptoms related to fungal infections of the skin and nails. It is relevant in contexts where additional symptomatic support is needed, helping to address groups of symptoms that may become intense or disruptive.


Relief from Discomfort and Skin Irritation

This treatment is commonly used across conditions characterized by symptoms related to inflammatory or irritative states caused by fungi. This includes fungal infections of the skin like athlete's foot, ringworm, and jock itch, as well as fungal nail infections (onychomycosis). The treatment may assist with easing symptoms such as pruritus (itching) and other associated discomfort.

“The treatment helps ease the symptom burden associated with common fungal skin manifestations.”

This provides support that helps ease the overall symptom load, contributing to improved day-to-day comfort.


Managing Visible Signs of Infection

Miclast is applied in scenarios where visible skin changes create noticeable physiological strain, which include redness, scaling, peeling, and flaking characteristic of fungal dermatoses. It is also relevant for fungal nail infections, helping to manage the associated appearance of damaged or discolored nails. The treatment supports general well-being during symptomatic phases and may assist with maintaining functional stability and a more normal appearance.


Quick Fact: Relief for Itching and Burning The treatment is considered relevant for easing discomfort symptoms related to inflammatory fungal states, and may be part of symptomatic management when itching and burning become noticeable.


Regulatory References

  1. DailyMed (NIH/FDA) Prescribing Information

Eligibility and Restrictions for Use

Miclast (Ciclopirox Olamine) eligibility is strictly defined by regulatory authorities to ensure appropriate use. The medication is contraindicated in any individual with a known hypersensitivity to the active substance or any of its components.

Eligibility is highly dependent on the patient's age and the specific formulation. Use of the dermal cream or suspension is approved for adults and pediatric patients 10 years of age and older. Safety and effectiveness have not been established in children younger than 10 years. The medicated nail lacquer is generally reserved for adults only, as use in adolescents under 18 years is not established.

For pregnant women, use is conditional and should occur only if the potential benefit justifies the potential risk to the fetus, reflecting a lack of adequate human safety data (FDA Category B). Caution is exercised in nursing mothers, as it is not known whether the drug is excreted in human milk.

Further restrictions apply to the nail lacquer. Its use requires careful consideration for patients with diabetic neuropathy due to associated procedural risks. Effectiveness and safety have not been studied in populations with a history of immunosuppression or organ transplant. The product must also not be used on open wounds or mucosal passages.

What should I know about interactions with other medicines?

The official interaction profile for Miclast (ciclopirox olamine) is structured by its status as a topical antifungal agent with minimal systemic absorption. Consequently, specific systemic drug-drug interactions involving major metabolic enzymes or drug transporters are generally absent from official regulatory documentation, as expected for a locally acting product.

Documented Interaction Restrictions

The documented interaction concerns relate primarily to co-administration restrictions defined in regulatory labels, focusing on the local treatment context.

Interaction Type Interacting Substance/Product Regulatory Restriction
Pharmacodynamic Caution Systemic Antifungal Agents for Onychomycosis Co-administration of the topical solution (nail lacquer) is not recommended due to the lack of clinical studies determining a potential reduction in the systemic agent's effectiveness.
Procedural Restriction Nail Polish or Other Cosmetic Nail Products These products must not be applied to the nails undergoing treatment with the topical solution.

Regulatory documents confirm that no interactions are specifically documented with food, alcohol, or common herbal supplements. The absence of listed CYP-enzyme or transporter-mediated interactions aligns with the drug's specialized, local route of administration.

Mechanism of Action

Disrupting Fungal Bioenergetics and Replication

This core mechanism involves Ciclopirox Olamine's ability to interfere directly with the fungal cell's ATP generation by inhibiting Complex III of the mitochondrial electron transport chain. This molecular blockade leads to a rapid collapse in ATP synthesis (cellular energy), while simultaneously disrupting cell division and integrity by acting as a chelator of essential polyvalent cations, like ferric iron ( Fe^3+). These combined actions lead to the resulting physiological consequence of pathogen control through fungicidal and fungistatic effects.


Modulating Localized Inflammatory Responses

The drug possesses a secondary, distinct mechanism that acts on the host's skin tissue, modulating the local physiological reaction. It functions as an inhibitor of key enzymes, Cyclooxygenase and 5-Lipoxygenase, within the arachidonic acid cascade. This suppresses the downstream production of potent pro-inflammatory mediators, such as prostaglandins and leukotrienes. This interference with the humoral inflammatory signaling contributes to the reduction of localized erythema (redness) and tissue irritation.

Dosage and Administration Information

Miclast (Ciclopirox Olamine) is strictly intended for topical use, administered only to the skin, nails, or scalp, and is not approved for use in the eyes or for internal consumption. The dermal forms, such as the 0.77% cream, gel, or suspension, are applied twice daily to the affected and surrounding skin, typically in the morning and evening. The suspension form requires vigorous shaking prior to each use to ensure proper ingredient mixture. Treatment for most skin infections is directed to continue for the full prescribed course, often requiring a total duration of up to four weeks, with diagnosis re-evaluation recommended if no improvement is observed by that point.

The 8% topical solution (nail lacquer) follows a different protocol designed for fungal nail infections. It is applied once daily, preferably at bedtime, onto the entire nail plate and surrounding skin. This long-term regimen necessitates specialized maintenance, requiring the user to remove the accumulated film using rubbing alcohol once every seven days. The successful completion of the up to 48-week course also involves the mandatory monthly professional removal of unattached, infected nail material by a healthcare provider. During treatment with any form, users are instructed to avoid covering the treated area with occlusive wrappings and to refrain from using cosmetic nail products on treated nails. Dosing instructions for children vary by product form, with the dermal cream generally not established for use in those under 10 years of age.

Recent Clinical Evidence

Research evidence / Overview of Studies for Miclast

The research foundation for Miclast (Ciclopirox Olamine) is built primarily on studies that have explored the application of the topical drug in structured clinical environments. The evidence base outlines the types of fungal conditions that have been the focus of regulated research, the key measurements used, and the areas where findings remain limited or uncertain.


Evidence for Use in Common Fungal Skin Infections (Dermatophytoses)

Research exploring common fungal skin infections, such as Athlete's Foot and ringworm, has focused on Randomized Controlled Trials (RCTs). Researchers used the drug in its topical formulations and monitored patient groups over defined treatment periods, typically lasting two to four weeks.

The research examined two main outcomes. First, they monitored Mycological Status (tracking fungal presence via lab tests). Second, they evaluated Clinical Response (assessing visible signs like redness and scaling). Findings describe patterns observed in the studies related to both the status of fungal presence and the status of clinical signs during the study period. However, long-term outcomes are not well characterized, restricting insight into the durability of the response.


Evidence from Studies of Fungal Nail Infections (Onychomycosis)

Research into onychomycosis involved long-duration, vehicle-controlled studies, requiring patients to be monitored for an extended duration, up to 48 weeks. The research examined several complex endpoints, including Total Response (Mycological and Clinical Status) and the Percentage of Nail Status over the study duration. Data for treating fingernail infections is less prominent, as most research focused on toenails.


What the Research Still Classifies as Uncertain or Limited

Comparative evidence against newer topical antifungals is often lacking in the public record. Data for certain specific groups, such as individuals with compromised immune systems, remain insufficient. While research provides insight into short-term changes, long-term effects are not fully established across all indications, and the evidence base is inherently limited by the challenges of long-term topical delivery.

Key Studies & References

  1. Ciclopirox Olamine Cream USP, 0.77% (Ciclopirox Cream) FOR DERMATOLOGIC USE ONLY. NOT FOR USE IN EYES. - DailyMed (FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about Miclast (FAQ)


Q: How quickly does Miclast typically start working for common fungal infections?

According to official product information, patients usually begin to notice clinical improvement in symptoms, such as relief from itching, within the first week of starting treatment for common fungal skin infections. Patients are generally advised to continue the full course of therapy as prescribed to support the complete resolution of the infection.


Q: What happens if I forget to apply a dose of Miclast?

If a dose is missed, regulatory guidance suggests applying it as soon as it is remembered. The guidance is to then continue with the regular schedule for the remaining applications. Consistent application supports the intended therapeutic outcome.


Q: Is it normal for the skin to peel a little after using Miclast for a few days?

Official adverse event reports list application site reactions like dryness and irritation as possible, though uncommon, effects. However, minor skin peeling is not typically specified as a common expected reaction in regulatory documentation. If severe irritation, redness, or a worsening rash occurs, it is recommended that patients discontinue use and contact a healthcare professional.


Q: Can Miclast be used for skin fold rashes that look red and itchy?

Yes, regulatory documents indicate that Miclast (Ciclopirox Olamine) is approved for the topical treatment of dermal infections that commonly affect skin folds. This includes conditions such as tinea cruris (jock itch) and cutaneous candidiasis (yeast infections), which often appear as red, itchy rashes.


Q: What should I do if my rash gets worse after I start using Miclast?

Official prescribing information advises that if signs of increased irritation are noticed at the application site—such as worsened redness, burning, swelling, or blistering—treatment should be discontinued. If this occurs, it is important to contact a healthcare professional for guidance.


Q: Do I need a prescription to buy Miclast?

In most regulatory settings, Miclast and its direct generic versions containing Ciclopirox Olamine are classified as a Prescription Drug (Rx Only). This means a healthcare provider's authorization is typically required to obtain the product.


Q: Are there any foods or drinks that should be avoided while using Miclast?

Because Miclast is a topical medication with minimal absorption into the bloodstream, official drug interaction documentation states that there are no specific restrictions regarding food or alcohol consumption while using the product.


Q: How long can I safely use Miclast before needing a doctor's review?

For most fungal skin infections, treatment is typically directed for up to four weeks. If a patient observes no clinical improvement in the infection after this four-week period, re-evaluation of the diagnosis by a healthcare professional is generally recommended.


Q: Why do people sometimes say they feel a cooling sensation when they apply Miclast?

While a cooling effect is not listed as a specific pharmacological action, the base of the Miclast formulation may contribute to certain sensations. The presence of solvents like alcohol in the solution or the water-based components in the cream may cause a transient feeling of cooling or slight stinging upon application.


Q: Are there generic versions of Miclast available?

Yes, the active ingredient in Miclast, Ciclopirox Olamine, is available in generic versions. These generic formulations contain the same active substance and are approved by regulatory bodies for the same uses as the branded product.


Q: What is the difference between Miclast cream and Miclast solution (if applicable)?

Both the cream and solution (or suspension) forms of Miclast are generally indicated for treating the same fungal skin infections. The primary difference lies in the base of the formulation. A healthcare provider typically selects the form that is best suited for the type of skin or area being treated.


Q: Are there any warnings for Miclast use in elderly patients?

Official clinical studies have not identified any major differences in response or adverse effects when comparing older individuals to younger adults. However, as is common with any medication, greater sensitivity in some older individuals cannot be entirely ruled out.


Q: What are the inactive ingredients in Miclast cream?

The official product information lists the inactive ingredients that make up the cream's base, which helps deliver the medication to the skin. These typically include agents like cetyl alcohol, stearyl alcohol, mineral oil, and purified water, along with other emulsifiers and preservatives.


Q: Does Miclast work for jock itch, or is it only for athlete's foot?

Miclast (Ciclopirox Olamine) is indicated for a broad range of fungal infections, including tinea cruris (commonly known as jock itch), as well as tinea pedis (athlete's foot). The medication's broad-spectrum nature makes it effective against these related conditions.


Q: Why might a fungal infection come back after stopping Miclast?

Official patient information notes that a fungal infection may recur if the full course of treatment, as prescribed, is not completed. This is intended to support the complete eradication of the infection.


Q: Is there a maximum number of applications per day for Miclast?

For treating most fungal infections of the skin with the cream or suspension, the recommended dosage is to apply the medication twice daily, once in the morning and once in the evening. This frequency aligns with the established guidance for using the product.

How should Miclast be stored and disposed of?

How to Store and Dispose of Miclast (Ciclopirox Olamine)

Storage Conditions

Miclast must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). It is essential to keep the product from freezing.

All forms must be stored in a closed container and kept out of reach of children. The Medicated Nail Lacquer requires additional precautions: it must be stored with the bottle tightly closed, protected from light, and kept away from heat and flame due to its flammability.

Disposal Instructions

Unused or expired Miclast should not be kept. Disposal must be conducted according to local and national regulations for pharmaceutical waste. To protect the environment, the product should not be released into drains or water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Miclast found in:

A-Z Index: